A Randomized, Double-blind, Multi-Center Phase 3 of ADI-PEG 20 plus best supportive Care (BSC) vs Placebo plus BSC in Subjects with Advanced Hepatocellular Carcinoma (HCC) who have Failed Prior Systemic Therapy
|Effective start/end date||9/27/11 → 12/30/15|
- Polaris Pharmaceuticals, Inc.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.